Since there is a considerable degree of heterogeneity with LGS, individualized approaches are necessary. The investigator firstly uses the antiepileptic drugs that currently approved by the Food and Drug Administration and available in our institute: lamotrigine, topiramate, clobazam, and clonazepam depended on seizure types. The investigator gave lamotrigine 1-20 mg/kg/day with slowly titration for tonic, tonic-clonic, atypical absences, and atonic seizures. Clobazam 0.25-3.5 mg/kg/day was added in the cases that refractory to lamotrigine and in the participants with myoclonic seizures. The investigator used clonazepam 0.04-0.2 mg/kg/day instead of clobazam in some cases when clobazam was not available. We used topiramate 1-10 mg/kg/day in the participants who refractory to lamotrigine and clobazam. In some cases, that refractory to the aforementioned antiepileptic drugs, the investigator gave zonisamide 1-20 mg/kg/day, levetiracetam 10-80 mg/kg/day, and nitrazepam 0.1-0.8 mg/kg/day [8].